Actavis CEO Says Health Law May Boost Generics Use
Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)
Most Recent Videos
Will Volatility Rise in the Fourth Quarter?
01:22 - Mouhammed Choukeir, chief investment officer at Kleinwort Benson, discusses the outlook for markets in the fourth quarter and his subsequent thoughts on investing. He speaks with Guy Johnson and Caroline Hyde on Bloomberg Television’s “On The Move.” (Source: Bloomberg)